Your browser is no longer supported. Please, upgrade your browser.
FOLD Amicus Therapeutics, Inc. daily Stock Chart
FOLD [NASD]
Amicus Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.57 Insider Own0.80% Shs Outstand256.97M Perf Week-6.73%
Market Cap2.42B Forward P/E- EPS next Y-0.97 Insider Trans-7.68% Shs Float252.71M Perf Month-1.26%
Income-344.80M PEG- EPS next Q-0.28 Inst Own- Short Float12.70% Perf Quarter-4.07%
Sales159.60M P/S15.18 EPS this Y-0.50% Inst Trans1.71% Short Ratio9.08 Perf Half Y-21.81%
Book/sh2.15 P/B4.39 EPS next Y28.70% ROA-41.10% Target Price18.04 Perf Year-10.36%
Cash/sh2.00 P/C4.71 EPS next 5Y-1.00% ROE-71.00% 52W Range7.11 - 14.61 Perf YTD-1.57%
Dividend- P/FCF- EPS past 5Y-10.10% ROI-49.50% 52W High-35.48% Beta1.57
Dividend %- Quick Ratio6.10 Sales past 5Y202.00% Gross Margin87.90% 52W Low32.63% ATR0.39
Employees508 Current Ratio6.20 Sales Q/Q136.90% Oper. Margin- RSI (14)45.92 Volatility3.69% 4.01%
OptionableYes Debt/Eq0.27 EPS Q/Q71.20% Profit Margin- Rel Volume1.52 Prev Close9.51
ShortableYes LT Debt/Eq0.27 EarningsNov 11 BMO Payout- Avg Volume3.54M Price9.43
Recom1.70 SMA20-5.27% SMA504.33% SMA200-16.01% Volume5,359,686 Change-0.84%
Nov-12-19Reiterated H.C. Wainwright Buy $18 → $20
Jun-17-19Initiated H.C. Wainwright Buy $18
Jun-05-19Reiterated Cantor Fitzgerald Overweight $20 → $19
Apr-05-19Initiated Janney Buy
Jan-30-19Initiated Cantor Fitzgerald Overweight $20
Oct-29-18Initiated Citigroup Neutral $12
Aug-17-18Downgrade Chardan Capital Markets Buy → Neutral $18 → $15
Oct-06-17Resumed Goldman Neutral
Sep-13-17Reiterated Chardan Capital Markets Buy $17.50 → $16.50
Aug-10-17Reiterated Chardan Capital Markets Buy $12.50 → $17.50
Jan-24-17Upgrade Robert W. Baird Neutral → Outperform $7 → $10
May-18-16Initiated BofA/Merrill Buy $10
Apr-14-16Initiated Robert W. Baird Neutral $9
Apr-12-16Reiterated Chardan Capital Markets Buy $10 → $15
Sep-16-15Downgrade Chardan Capital Markets Buy → Neutral $17
Jun-16-15Reiterated Chardan Capital Markets Buy $14 → $17.50
May-29-15Initiated Chardan Capital Markets Buy $14
Dec-20-12Reiterated Canaccord Genuity Buy $11 → $6
Dec-20-12Downgrade Capstone Investments Buy → Hold $3
Nov-01-12Initiated Capstone Investments Buy $7
Dec-11-19 11:30AM  Why Is Amicus Therapeutics (FOLD) Up 6% Since Last Earnings Report? Zacks
Dec-05-19 10:53PM  Hedge Funds Cashed Out Of Amicus Therapeutics, Inc. (FOLD) Too Early Insider Monkey -6.79%
Dec-04-19 09:28AM  Amicus Therapeutics, Inc. (FOLD) Shares March Higher, Can It Continue? Zacks
Nov-21-19 07:48AM  Edited Transcript of FOLD earnings conference call or presentation 11-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-20-19 10:09AM  Co-working space takes aim at Lake Nona American City Business Journals
Nov-19-19 03:03PM  How to Find Cheap Buy-Ranked Stocks Trading Under $10 Zacks
Nov-18-19 09:24AM  Is Amicus Therapeutics (NASDAQ:FOLD) A Risky Investment? Simply Wall St.
Nov-12-19 09:52AM  Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat Zacks
09:33AM  Company News For Nov 12, 2019 Zacks
09:25AM  Done deal: Tavistock sells land to New Jersey biotech firm American City Business Journals
Nov-11-19 08:15AM  Amicus Therapeutics (FOLD) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM  Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates GlobeNewswire
Nov-08-19 12:47PM  Earnings Reports for the Week of Nov. 11-15 (DHI, NVDA, WMT) Kiplinger
Nov-07-19 11:41AM  Bet on This Biotech Before Earnings Schaeffer's Investment Research
11:15AM  Cronos (CRON) to Report Q3 Earnings: What's in the Cards? Zacks
10:32AM  Tilray (TLRY) to Report Q3 Earnings: What's in the Cards? Zacks
Nov-05-19 11:50AM  CannTrust (CTST) to Report Q3 Earnings: What's in Store? Zacks
11:24AM  What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings? Zacks
11:13AM  Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards? Zacks
09:15AM  PCTEL (PCTI) Gears Up for Q3 Earnings: What's in Store? Zacks
Nov-04-19 11:42AM  What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks
10:30AM  Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy? Zacks
07:13AM  CenturyLink (CTL) Gears Up for Q3 Earnings: What's in Store? Zacks
Oct-30-19 07:00AM  Amicus Therapeutics to Announce Third Quarter 2019 Financial Results on November 11, 2019 GlobeNewswire
Oct-24-19 04:52PM  Were Hedge Funds Right About Souring On Amicus Therapeutics, Inc. (FOLD)? Insider Monkey
07:00AM  Amicus Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 48th Annual Meeting of the Child Neurology Society GlobeNewswire
Oct-10-19 07:30AM  Amicus Therapeutics Announces Preliminary Third Quarter 2019 Revenue and Financial Outlook at 2019 Analyst Day GlobeNewswire
Oct-03-19 08:33PM  Edited Transcript of FOLD earnings conference call or presentation 8-Aug-19 12:30pm GMT Thomson Reuters StreetEvents +6.60%
08:09AM  Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) A Volatile Stock? Simply Wall St.
Oct-02-19 07:00AM  Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study of AT-GAA at the 24th International Annual Congress of the World Muscle Society GlobeNewswire
Oct-01-19 07:00AM  Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019 GlobeNewswire
Sep-07-19 09:30AM  Why Is Amicus Therapeutics (FOLD) Down 18.9% Since Last Earnings Report? Zacks
Sep-04-19 07:00AM  Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019 GlobeNewswire
Aug-19-19 09:35AM  Is Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) CEO Overpaid Relative To Its Peers? Simply Wall St.
Aug-12-19 10:59AM  Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View Zacks
Aug-10-19 01:30AM  Amicus Therapeutics Inc (FOLD) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 09:25AM  Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:00AM  Amicus Therapeutics Announces Second Quarter 2019 Financial Results and Corporate Updates GlobeNewswire
Aug-02-19 07:00AM  Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina GlobeNewswire -6.43%
Aug-01-19 10:33AM  Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for Zacks
06:00AM  Amicus Announces Positive Interim Clinical Data for AAV Gene Therapy in Children with CLN6 Batten Disease GlobeNewswire
Jul-29-19 07:00AM  Amicus Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019 GlobeNewswire
Jul-22-19 01:07PM  New Jersey biotech firm to open Lake Nona office, lab American City Business Journals
Jul-04-19 01:39PM  If You Had Bought Amicus Therapeutics (NASDAQ:FOLD) Stock Five Years Ago, You Could Pocket A 227% Gain Today Simply Wall St.
11:51AM  Why Amicus Therapeutics' Stock Perked Up in June Motley Fool
Jul-02-19 07:30AM  Amicus Therapeutics and Catalent Biologics Enter Strategic Partnership for Gene Therapy Development and Manufacturing GlobeNewswire
Jul-01-19 07:00AM  Amicus Therapeutics and Brammer Bio, a part of Thermo Fisher Scientific, Enter Strategic Gene Therapy Development and Manufacturing Collaboration GlobeNewswire
Jun-19-19 09:59PM  Is Amicus Therapeutics, Inc. (FOLD) A Good Stock To Buy? Insider Monkey
Jun-13-19 07:30AM  Amicus Therapeutics Adds Key Executives in Gene Therapy Science and Global Commercial Leadership GlobeNewswire
Jun-12-19 05:49PM  New Jersey biotech firm scales back Lake Nona plans American City Business Journals
08:44AM  2 Small Biotechs With Sagging Shares but Promising Prospects TheStreet.com
Jun-07-19 09:30AM  Why Is Amicus Therapeutics (FOLD) Down 9.6% Since Last Earnings Report? Zacks
Jun-05-19 11:25AM  Edited Transcript of FOLD earnings conference call or presentation 8-May-19 12:30pm GMT Thomson Reuters StreetEvents
Jun-04-19 04:01PM  Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock GlobeNewswire +7.82%
Jun-03-19 07:00AM  Amicus Therapeutics to Present at Upcoming Scientific and Investor Conferences GlobeNewswire
May-31-19 07:34AM  The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering Benzinga
May-30-19 09:00PM  Amicus Therapeutics Prices Underwritten Offering of Common Stock GlobeNewswire -9.79%
04:29PM  Why NIO, PVH, and Amicus Therapeutics Slumped Today Motley Fool
02:11PM  Here's Why Amicus Therapeutics Fell as Much as 15.6% Today Motley Fool
10:34AM  2 Ultra-High-Growth Biotech Stocks to Buy Now Motley Fool
07:33AM  The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug Benzinga
May-29-19 04:14PM  Amicus Therapeutics Announces Public Offering of Common Stock GlobeNewswire
11:36AM  Amicus, Penn expand gene therapy collaboration in a big way American City Business Journals
06:30AM  Amicus Therapeutics and the University of Pennsylvania Announce Major Expansion of Gene Therapy Collaboration GlobeNewswire
May-13-19 05:00PM  Amicus Therapeutics Appoints Burke W. Whitman to its Board of Directors GlobeNewswire -5.18%
May-10-19 07:00AM  Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference GlobeNewswire
May-09-19 03:21PM  Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1 Zacks
May-08-19 04:23PM  Amicus Therapeutics Inc (FOLD) Q1 2019 Earnings Call Transcript Motley Fool
08:25AM  Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:24AM  Amicus Therapeutics: 1Q Earnings Snapshot Associated Press
07:00AM  Amicus Therapeutics Announces First Quarter 2019 Financial Results and Corporate Updates GlobeNewswire
May-03-19 09:51AM  What's in Store for Catalyst Pharma (CPRX) Q1 Earnings? Zacks
May-01-19 10:33AM  Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-30-19 08:00PM  3 Growth Stocks to Buy and Hold for the Next 50 Years Motley Fool
08:06AM  The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering Benzinga
06:00AM  Amicus Therapeutics Presents Positive Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting GlobeNewswire
Apr-25-19 07:00AM  Amicus Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019 GlobeNewswire
Apr-15-19 03:36PM  FOLD Stock Could See a Surge Soon, Says Signal Schaeffer's Investment Research
12:00PM  Amicus Therapeutics to Present Preclinical Pompe Disease Gene Therapy Data at the American Society of Gene & Cell Therapy (ASGCT) 22nd Annual Meeting GlobeNewswire
Apr-10-19 12:47PM  What Investors Should Know About Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Financial Strength Simply Wall St.
Apr-05-19 12:27PM  Janney: Amicus Therapeutics Has Significant Upside From Gene Therapy Pipeline Benzinga
Mar-30-19 09:30AM  Amicus Therapeutics (FOLD) Up 12.4% Since Last Earnings Report: Can It Continue? Zacks
Mar-29-19 07:10AM  Detailed Research: Economic Perspectives on Five Below, INVESCO MORTGAGE CAPITAL INC, Amicus Therapeutics, Akamai Technologies, Kura Oncology, and Columbus McKinnon What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-20-19 02:09PM  Edited Transcript of FOLD earnings conference call or presentation 28-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
07:00AM  Amicus Therapeutics Issued Two U.S. Patents for Pompe Enzyme ATB200 GlobeNewswire
Mar-07-19 02:52PM  Amicus Therapeutics Looks Impressive If it Can Rally Above $18 TheStreet.com
Mar-06-19 02:39PM  Will Amicus Therapeutics, Inc.s (NASDAQ:FOLD) Earnings Grow In The Years Ahead? Simply Wall St.
Mar-01-19 11:59AM  Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018 Zacks +15.04%
Feb-28-19 12:04PM  Amicus Therapeutics Inc (FOLD) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:00AM  Amicus Therapeutics Announces Full-Year 2018 Financial Results and 2019 Corporate Updates GlobeNewswire
06:30AM  Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-26-19 07:32AM  N.J. biotech firm expanding to Philadelphia, creating 200 new jobs American City Business Journals
07:00AM  Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia GlobeNewswire
Feb-25-19 09:02AM  What's in Store for Universal Health (UHS) Q4 Earnings? Zacks +5.87%
04:00AM  U.S. FDA Grants Breakthrough Therapy Designation (BTD) to Amicus AT-GAA in Late Onset Pompe Disease GlobeNewswire
Feb-22-19 04:36PM  What's in Store for Teladoc's (TDOC) Q4 Earnings? Zacks
Feb-21-19 10:31AM  Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Feb-20-19 09:32AM  Tenet Healthcare (THC) Q4 Earnings: What's in the Offing? Zacks
Feb-13-19 07:30AM  New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Feb-12-19 07:00AM  Amicus Therapeutics to Announce Full-Year 2018 Financial Results on February 28, 2019 GlobeNewswire
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize Galafold as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies; and a strategic manufacturing agreement with Catalent Biologics. The company has a strategic manufacturing collaboration with Thermo Fisher Scientific for conducting preclinical and clinical-stage gene therapy programs for CLN6, CLN3, and other Batten disease programs. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Crowley John FChairman & CEODec 02Option Exercise3.8220,00076,400755,694Dec 04 05:17 PM
Crowley John FChairman & CEODec 02Sale10.3820,000207,618735,694Dec 04 05:17 PM
Crowley John FChairman & CEONov 25Option Exercise3.8240,000152,800775,694Nov 27 05:03 PM
Crowley John FChairman & CEONov 25Sale10.0140,000400,204735,694Nov 27 05:03 PM
Crowley John FChairman & CEONov 15Option Exercise5.1320,000102,600755,694Nov 19 06:17 PM
Crowley John FChairman & CEONov 15Sale9.5220,000190,390735,694Nov 19 06:17 PM
Crowley John FChairman & CEONov 08Option Exercise5.1320,000102,600755,694Nov 12 05:50 PM
Crowley John FChairman & CEONov 08Sale9.0220,000180,414735,694Nov 12 05:50 PM
Crowley John FChairman & CEOOct 11Sale8.0114,500116,073735,694Oct 15 05:03 PM
Crowley John FChairman & CEOSep 11Option Exercise3.8220,00076,400770,194Sep 13 05:09 PM
Crowley John FChairman & CEOSep 11Sale10.0520,000201,030750,194Sep 13 05:09 PM
WHITMAN BURKE WDirectorAug 23Buy10.074,94549,79621,612Aug 27 07:59 PM
Crowley John FChairman & CEOAug 01Option Exercise3.8220,00076,400770,194Aug 02 04:40 PM
Crowley John FChairman & CEOAug 01Sale12.5420,000250,736750,194Aug 02 04:40 PM
Crowley John FChairman & CEOJul 01Option Exercise3.8220,00076,400770,194Jul 02 05:18 PM
Crowley John FChairman & CEOJul 01Sale12.4720,000249,462750,194Jul 02 05:18 PM
RAAB MICHAELDirectorJun 03Option Exercise7.155,00035,75013,895Jun 04 04:35 PM
Crowley John FChairman & CEOJun 03Option Exercise3.8220,00076,400770,399Jun 04 04:34 PM
Crowley John FChairman & CEOJun 03Sale11.1520,000223,072750,399Jun 04 04:34 PM
RAAB MICHAELDirectorJun 03Sale11.165,00055,7768,895Jun 04 04:35 PM
Crowley John FChairman & CEOMay 01Option Exercise3.8220,00076,400770,399May 02 04:22 PM
Crowley John FChairman & CEOMay 01Sale13.5120,000270,154750,399May 02 04:22 PM
Barth JayChief Medical OfficerApr 05Option Exercise2.2950,000114,500179,767Apr 08 04:52 PM
Barth JayChief Medical OfficerApr 05Sale14.2050,000710,195129,767Apr 08 04:52 PM
Crowley John FChairman & CEOApr 01Option Exercise3.5020,00069,968688,081Apr 03 06:29 PM
Crowley John FChairman & CEOApr 01Sale13.6320,000272,626668,081Apr 03 06:29 PM
Crowley John FChairman & CEOMar 01Option Exercise3.5420,00070,848688,081Mar 05 05:47 PM
Crowley John FChairman & CEOMar 01Sale13.6020,000271,979668,081Mar 05 05:47 PM
Barth JayChief Medical OfficerFeb 25Option Exercise2.7070,000188,725173,497Feb 27 05:30 PM
Barth JayChief Medical OfficerFeb 25Sale12.5270,000876,134129,767Feb 27 05:30 PM
Crowley John FChairman & CEOFeb 01Option Exercise3.8220,00076,400688,081Feb 05 06:10 PM
Crowley John FChairman & CEOFeb 01Sale12.1220,000242,320668,081Feb 05 06:10 PM
Campbell Bradley LChief Operating OfficerJan 22Option Exercise10.3636,000372,960275,360Jan 24 05:06 PM
Campbell Bradley LChief Operating OfficerJan 22Sale11.8136,000425,135239,360Jan 24 05:06 PM
Do HungChief Science OfficerJan 16Option Exercise4.8235,024168,749474,937Jan 17 08:48 PM
Do HungChief Science OfficerJan 16Sale12.0536,669441,861438,268Jan 17 08:48 PM
Crowley John FChairman & CEOJan 15Option Exercise10.36103,5001,072,260771,581Jan 17 08:47 PM
Do HungChief Science OfficerJan 15Option Exercise3.958,20032,430456,513Jan 17 08:48 PM
Do HungChief Science OfficerJan 15Sale12.0016,600199,200439,913Jan 17 08:48 PM
Crowley John FChairman & CEOJan 15Sale11.71103,5001,212,296668,081Jan 17 08:47 PM